deltatrials
Terminated OBSERVATIONAL NCT03935126

Global Atrophie Biomarker Evaluation Study (GABiE) (GABiE)

A Biomarker Evaluation Study in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration (AMD) Evaluating the Use of Microperimetry (Fundus-controlled Perimetry) and Swept Source-OCT in Assessing Changes in Retinal Sensitivity and Anatomy Over Time.

Sponsor: Boehringer Ingelheim

Conditions Age-related Macular Degeneration
Interventions Diagnostics
Updated 19 times since 2019 Last updated: Apr 29, 2021 Started: May 7, 2019 Primary completion: May 6, 2020 Completion: May 14, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Not due to safety reasons

Other terminated trials from Boehringer Ingelheim

See all terminations from Boehringer Ingelheim

Other Age-related Macular Degeneration trials with similar outcome

Browse all Age-related Macular Degeneration trials

Listed as NCT03935126, this observational or N/A phase trial focuses on Age-related Macular Degeneration and remains terminated or withdrawn. Sponsored by Boehringer Ingelheim, it has been updated 19 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jun 2021 · 4 months · monthly snapshot~Jun 2021 – ~Dec 2021 · 6 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated

  4. Jun 2021 — Dec 2021 [monthly]

    Terminated

  5. Feb 2021 — Jun 2021 [monthly]

    Terminated

▶ Show 14 earlier versions

  1. Jan 2021 — Feb 2021 [monthly]

    Terminated

    Phase: NA → None

  2. Jun 2020 — Jan 2021 [monthly]

    Terminated NA

    Status: Suspended → Terminated

  3. May 2020 — Jun 2020 [monthly]

    Suspended NA

    Status: Recruiting → Suspended

  4. Apr 2020 — May 2020 [monthly]

    Recruiting NA

  5. Mar 2020 — Apr 2020 [monthly]

    Recruiting NA

  6. Feb 2020 — Mar 2020 [monthly]

    Recruiting NA

  7. Jan 2020 — Feb 2020 [monthly]

    Recruiting NA

  8. Dec 2019 — Jan 2020 [monthly]

    Recruiting NA

  9. Nov 2019 — Dec 2019 [monthly]

    Recruiting NA

  10. Oct 2019 — Nov 2019 [monthly]

    Recruiting NA

  11. Sep 2019 — Oct 2019 [monthly]

    Recruiting NA

  12. Aug 2019 — Sep 2019 [monthly]

    Recruiting NA

  13. Jul 2019 — Aug 2019 [monthly]

    Recruiting NA

  14. Jun 2019 — Jul 2019 [monthly]

    Recruiting NA

    First recorded

May 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boehringer Ingelheim
Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations